Effect of BRX‐220 against Peripheral Neuropathy and Insulin Resistance in Diabetic Rat Models
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A bstract: Bimoclomol (BML), a symptomatic antidiabetic agent, has been developed by Biorex R & D Co. to treat diabetic neuropathy and retinopathy. BRX‐220, an orally active member of the BRX family, has been developed to treat diabetic complications and insulin resistance (IR) as a follow‐up compound. The effect of BRX‐220 on peripheral neuropathy was examined in rats with diabetes (type 1) induced by administration of a β‐cell toxin, streptozotocin (STZ, 45 mg/kg iv). Nerve functions were evaluated by electrophysiological measurements of muscle motor and sensory nerve conduction velocities (MNCV and SNCV, respectively). MNCV and SNCV decreased in diabetic rats by 25% (p < 0.001). A 1‐month preventive treatment with BRX‐220 (2.5, 5, 10, and 20 mg/kg po) dose‐dependently improved diabetes‐related deficits in MNCV (51.3%, 71.3%, 86.1%, and 91.3%) and SNCV (48.9%, 68.5%, 86.1%, and 93.2%). Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes). Severe IR was detected in STZ diabetic and ZDF rats. This resistance was significantly (p < 0.05) reduced by BRX‐220 treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Negative consequences of glycation
Brownlee, M. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80078-5 · Cited by 284
Cited by
HSP72 protects against obesity-induced insulin resistance
Chung, J., Nguyen, A.-K., Henstridge, D. C., Holmes, A. G., Chan, M. H. S., Mesa, J. L., Lancaster, G. I., Southgate, R. J., Bruce, C. R., Duffy, S. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705799105 · Cited by 553
Membranes: A meeting point for lipids, proteins and therapies
Escribá, P. V., González‐Ros, J. M., Goñi, F. M., Kinnunen, P. K. J., Vigh, L., Sánchez‐Magraner, L., Fernández, A. M., Busquets, X., Horváth, I., & Barceló‐Coblijn, G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00281.x · Cited by 454
“A close chemical relative of the membrane-intercalating drug candidate, the hydroxylamine bimoclomol [276, 277], BRX-220, has been reported to improve insulin sensitivity of both Zucker diabetic fatty rats and streptozotocin-diabetic rats [278].”
BackgroundHeat shock proteins in the regulation of apoptosis: new strategies in tumor therapy
Sreedhar, A. S., & Csermely, P. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.004 · Cited by 418
Heat shock proteins as emerging therapeutic targets
Sõti, C., Nagy, E., Giricz, Z., Vígh, L., Csermely, P., & Ferdinandy, P. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706396 · Cited by 380
Bruce, C. R., Carey, A. L., Hawley, J. A., & Febbraio, M. A. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2338 · Cited by 318
Metadata
- Authors
- KÜRTHY, M., MOGYORÓSI, T., NAGY, K., KUKORELLI, T., JEDNÁKOVITS, A., TÁLOSI, L., & BÍRÓ, K.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 967
- Issue
- 1
- Pages
- 482-489
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2102667122
- Cited by
- 53
- References
- 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of BRX‐220 against Peripheral Neuropathy and Insulin Resistance in Diabetic Rat Models. https://app.cochat.ai/papers/10.1111/j.1749-6632.2002.tb04306.x
- The paper
- KÜRTHY, M., MOGYORÓSI, T., NAGY, K., KUKORELLI, T., JEDNÁKOVITS, A., TÁLOSI, L., & BÍRÓ, K. (2002). Effect of BRX‐220 against Peripheral Neuropathy and Insulin Resistance in Diabetic Rat Models. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2002.tb04306.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.